Table 1 Summary of demographic and clinical characteristics of ZEBRA trial study cohort
ZEBRA 1 | Placebo | Zibotentan | |
n= | 7 | 6 | |
Sex | Male | 1 | 2 |
Female | 6 | 4 | |
Ethnicity | White | 7 | 6 |
Subset | Diffuse | 2 | 1 |
Limited | 5 | 5 | |
ANA | |||
ACA | 5 | 3 | |
ARA | 1 | 2 | |
ATA | 0 | 0 | |
Other | 1 | 1 | |
Age (years) mean (SD) | 65 (7) | 62 (7) | |
SSc duration (years) mean (SD) | 9 (7) | 11 (7) | |
SRC, n (%) | 1 (14%) | 0 | |
PH, n (%) | 0 | 0 | |
DU, n (%) | 2 (28%) | 2 (33%) | |
Vasodilator, n (%) | 5 (71%) | 5 (83%) | |
DMARD, n (%) | 1 (14%) | 1 (17%) | |
ZEBRA 2A | Placebo | Zibotentan | |
n= | 2 | 2 | |
Sex | Male | 0 | 1 |
Female | 2 | 1 | |
Ethnicity | White | 2 | 1 |
Asian | 0 | 1 | |
Age (years) | 57, 34 | 63, 65 | |
SSc duration (years) | 1, 2 | 1, 1 | |
SRC (n) | 2 | 2 | |
PH (n) | 0 | 0 | |
DU (n) | 0 | 0 | |
Vasodilator (n) | 2 | 2 | |
DMARD (n) | 1 | 2 | |
ZEBRA 2B | |||
n= | 6 | ||
Sex | Male | NA | 5 |
Female | NA | 1 | |
Ethnicity | White | NA | 4 |
Black | NA | 1 | |
Mixed-race | 1 | ||